@article{JTD23100,
author = {Takaki Akamine and Gouji Toyokawa and Tetsuzo Tagawa and Takashi Seto},
title = {Atezolizumab in non-squamous non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 26},
year = {2018},
keywords = {},
abstract = {Immune therapy opened a new era in treatment of advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) targeting the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have achieved great success over conventional cytotoxic chemotherapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/23100}
}